Prostate Cell News Volume 8.41 | Oct 27 2017

TOP STORY

The p53‐Inducible Long Noncoding RNA TRINGS Protects Cancer Cells from Necrosis under Glucose Starvation

Investigators showed that under glucose starvation condition, p53 directly upregulates a novel lncRNA named TRINGS (Tp53‐regulated inhibitor of necrosis under glucose starvation) in human tumor cells. [EMBO J] Abstract

(Ranked by impact factor of the journal)

Prostate Cancer Cells Express More Androgen Receptor (AR) following Androgen Deprivation, Improving Recognition by AR-Specific T Cells

Scientists investigated whether an antigen-specific mechanism of resistance to androgen-deprivation therapy may result in enhanced AR-specific T-cell immune recognition, and whether this might be strategically combined with an antitumor vaccine targeting the AR. [Cancer Immunol Res] Abstract

Reactivation of Androgen Receptor-Regulated Lipid Biosynthesis Drives the Progression of Castration-Resistant Prostate Cancer

Researchers examined the androgen receptor (AR) cistrome in a prostate cancer cell line-derived castration-resistant prostate cancer (CRPC) model using integrated bioinformatical analyses. They found that the AR cistrome is largely retained in the CRPC stage. [Oncogene] Full Article

Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer

The authors showed that overexpression of ferroportin (FPN) induces profound effects in cells representative of multiple histological subtypes of prostate cancer by activating different but converging pathways. Induction of FPN induced autophagy and activated the transcription factors p53 and KLF6 and their common downstream target, p21. [Antioxid Redox Signal] Abstract

Placenta-Specific1 (PLAC1) Is a Potential Target for Antibody-Drug Conjugate-Based Prostate Cancer Immunotherapy

Scientists generated and evaluated an anti PLAC1-based antibody drug conjugate for targeted immunotherapy of prostate cancer. [Sci Rep] Full Article

Autoantibodies against the Cell Surface-Associated Chaperone GRP78 Stimulate Tumor Growth via Tissue Factor

Investigators explored the interplay between the autoantibodies against cell surface-associated GRP78, tissue factor expression/activity and prostate cancer progression. [J Biol Chem] Full Article

Predictive Value of Epithelial-Mesenchymal-Transition (EMT) Signature and PARP-1 in Prostate Cancer Radioresistance

Researchers conducted a retrospective analysis to investigate the significance of radiation-induced EMT and consequential changes to the tumor microenvironment in biochemical recurrence and response to radiotherapy in prostate cancer patients. [Prostate] Abstract

The 22Rv1 Prostate Cancer Cell Line Carries Mixed Genetic Ancestry: Implications for Prostate Cancer Health Disparities Research Using Pre-Clinical Models

The authors used 29 established Ancestry Informative Marker single nucleotide polymorphisms to conduct DNA ancestry analysis and assign ancestral proportions to a panel of five prostate cancer cell lines that included 22Rv1, PC3, DU145, MDA-PCa-2b, and RC-77T/E. [Prostate] Abstract

Highly Aggressive Rat Prostate Tumors Rapidly Precondition Regional Lymph Nodes for Subsequent Metastatic Growth

Investigators examined in what ways MatLyLu rat prostate tumors with high metastatic capacity influence regional lymph nodes prior to metastatic establishment compared to AT1 rat prostate tumors with low metastatic potential. [PLoS One] Full Article

Targeting Immunosuppressive Adenosine in Cancer

The authors describe the complex interplay of adenosine and adenosine receptors in the development of primary tumors and metastases and discuss the merits of targeting one or more components that compose the adenosinergic pathway. [Nat Rev Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Dana-Farber Cancer Institute Joins the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy announced that researchers at Dana-Farber Cancer Institute have joined its network. Dana-Farber is a leader in cancer research and brings a team of experts who will collaborate with Parker Institute investigators to enhance and expand research projects and clinical trials. [Dana-Farber Cancer Institute] Press Release

AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

AbbVie and Harpoon Therapeutics announced that they have entered an immuno-oncology research collaboration. [AbbVie, Inc.] Press Release

ORIC Pharmaceuticals Announces First Subject Dosed in Phase I Clinical Study of Novel GR Antagonist with Planned Development for Oncology

ORIC Pharmaceuticals announced that the first subject in a Phase Ia clinical study has been dosed with ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor. [ORIC Pharmaceuticals (PR Newswire Association LLC)] Press Release

US March for Science Group Faces Growing Pains

The US group that sparked the global March for Science movement is facing complaints about its management practices as it files for non-profit status and signals its intent to continue as “a movement to advance science and its role in public life. [Nature News] Editorial

Key Legislator Tells Trump Officials to Back Off on Proposed Overhead Spending Cap for NIH

An influential legislator wants President Donald Trump’s administration and fellow Republicans to drop the notion of capping overhead costs on grants funded by the National Institutes of Health (NIH). [ScienceInsider] Editorial

China Announces Plans to Fast-Track Drug Approval

China is overhauling its drug-approval system to let companies bring their treatments to market quicker and more easily. The Communist Party of China and the State Council, two of the country’s most authoritative bodies, announced plans to reduce the backlog of medicines awaiting approval by the China Food and Drug Administration. [Nature News] Editorial

NEW 73^rd Canadian Urological Association (CUA) Annual Meeting
June 23-26, 2018
Halifax, Nova Scotia, Canada

Visit our events page to see a complete list of events in the community.

NEW PhD Studentships – Prostate Cancer (Institute of Cancer Research)

Assistant Member – Prostate Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute)

Postdoctoral Position – Cancer Biology (The Henry Ford Health System)

Doctoral Student – Prostate Cancer (Lund University)

Director – Stanford Cancer Institute (Stanford University)

Postdoctoral Position – Cancer Biology and Epigenetics (Duke University)

Researcher – Cancer Biology (University of Cincinnati)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Postdoctoral Fellow – Drug Discovery (Vancouver Prostate Centre)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.